论文部分内容阅读
目的评价Ⅱ~Ⅲ期老年胃癌患者根治术后,行同步放化疗(RCT)与单纯化疗(CT)的临床疗效和不良反应。方法选择接受胃癌根治术后病理分期为Ⅱ~Ⅲ期的老年胃癌患者84例,RCT组48例,CT组36例。观察分析患者1、2、3年生存率、复发率及不良反应发生情况。结果 RCT组与CT组的1、2、3年生存率分别为87.5%、77.0%、66.7%和77.8%、55.5%、44.4%,2组间2年、3年生存率差异均有统计学意义(P<0.05)。RCT组与CT组1、2、3年复发率分别为8.3%、16.7%、29.2%和13.9%、38.9%、52.8%,2组间2年、3年复发率差异均有统计学意义(P<0.05)。RCT组粒细胞下降、贫血、呕吐、外周神经毒性的发生率与CT组相似;恶心(P=0.004)、体质量减轻(P=0.016)的发生率高于CT组。结论Ⅱ~Ⅲ期老年胃癌根治术后患者,RCT较CT可提高2年、3年生存率,降低局部复发率;RCT组主要不良反应为恶心、体质量减轻,通过辅助营养支持,可以耐受治疗。
Objective To evaluate the clinical efficacy and side effects of concurrent chemoradiotherapy (RCT) and chemotherapy alone (CT) in patients with stage Ⅱ ~ Ⅲ advanced gastric cancer after radical operation. Methods Eighty-four elderly patients with gastric cancer who underwent radical resection of gastric cancer from stage Ⅱ to Ⅲ were selected, 48 patients in RCT group and 36 patients in CT group. Observe and analyze the patients 1, 2, 3-year survival rate, recurrence rate and adverse reactions. Results The 1, 2, 3-year survival rates of RCT group and CT group were 87.5%, 77.0%, 66.7% and 77.8%, 55.5% and 44.4%, respectively. There was statistical difference between 2 and 3-year survival rates Significance (P <0.05). The recurrence rates at 1, 2 and 3 years in RCT group and CT group were 8.3%, 16.7%, 29.2% and 13.9%, 38.9% and 52.8% respectively. There was significant difference in recurrence rates between 2 and 3 years P <0.05). The incidences of neutropenia, anemia, vomiting and peripheral neurotoxicity in RCT group were similar to those in CT group. The incidence of nausea (P = 0.004) and weight loss (P = 0.016) was higher in CTL group than in CT group. Conclusions Patients with stage II-III elderly patients with gastric cancer who underwent radical operation showed that RCT increased the 2-year and 3-year survival rates and decreased the local recurrence rate. The main side effects were nausea and weight loss in RCT group, which could be tolerated by auxiliary nutritional support treatment.